📊 AXGN Key Takeaways
Is Axogen, Inc. (AXGN) a Good Investment?
Despite strong revenue growth of 20.2% YoY and an impressive 74.3% gross margin, Axogen is unprofitable with negative operating income of -$7.8M and deteriorating net income that declined 57.6% YoY. The company is burning cash with negative free cash flow of -$2.9M while carrying substantial debt of $48.4M, creating significant financial strain that undermines growth quality.
Axogen shows strong top-line momentum and attractive unit economics, with 20.2% revenue growth and a 74.3% gross margin indicating a differentiated, high-value product portfolio. However, the business is not yet consistently profitable, with negative operating income, worsening net losses, weak interest coverage, and slightly negative free cash flow limiting the quality of that growth. The balance sheet and liquidity are solid enough to support execution, but fundamentals still require proof of durable earnings conversion.
Why Buy Axogen, Inc. Stock? AXGN Key Strengths
- Strong revenue growth of 20.2% YoY demonstrates market demand
- Excellent gross margin of 74.3% indicates pricing power and operational efficiency in core business
- Solid liquidity position with current ratio of 5.11x and $35.5M cash buffer
- Revenue growth is strong at 20.2% YoY, showing continued commercial adoption
- Gross margin of 74.3% suggests strong pricing power and favorable product economics
- Liquidity is robust, with a 5.11x current ratio, 3.31x quick ratio, and moderate 0.38x debt/equity
AXGN Stock Risks: Axogen, Inc. Investment Risks
- Persistent operating losses of -$7.8M indicate inability to convert revenue growth into profitability
- Negative free cash flow of -$2.9M and operating cash flow of only $812K despite $225.2M revenue signals operational inefficiency
- High debt burden of $48.4M with negative interest coverage ratio of -3.4x creates refinancing and solvency risk
- Deteriorating net income (-57.6% YoY) and negative ROE/ROA suggest fundamental business model challenges
- Net income deteriorated 57.6% YoY, showing profitability remains fragile
- Operating margin is still negative at -3.5%, so scale has not yet translated into sustained earnings
- Interest coverage is negative and free cash flow remains below zero, increasing execution risk if losses persist
Key Metrics to Watch
- Path to operating profitability and timeline to positive operating margins
- Free cash flow generation and ability to service $48.4M debt without dilution
- Operating expense management as a percentage of revenue to close profitability gap
- Operating margin and net income trend toward sustained profitability
- Free cash flow and operating cash flow conversion as revenue grows
Axogen, Inc. (AXGN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 5.11x current ratio provides a solid financial cushion.
AXGN Profit Margin, ROE & Profitability Analysis
AXGN vs Healthcare Sector: How Axogen, Inc. Compares
How Axogen, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Axogen, Inc. Stock Overvalued? AXGN Valuation Analysis 2026
Based on fundamental analysis, Axogen, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Axogen, Inc. Balance Sheet: AXGN Debt, Cash & Liquidity
AXGN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Axogen, Inc.'s revenue has grown significantly by 77% over the 5-year period, indicating strong business expansion. The most recent EPS of $-0.51 indicates the company is currently unprofitable.
AXGN Revenue Growth, EPS Growth & YoY Performance
AXGN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $48.6M | $708.0K | $0.01 |
| Q2 2025 | $47.9M | $579.0K | $0.01 |
| Q1 2025 | $41.4M | -$3.8M | $-0.08 |
| Q3 2024 | $41.3M | -$1.9M | $-0.04 |
| Q2 2024 | $38.2M | -$1.9M | $-0.04 |
| Q1 2024 | $36.7M | -$6.6M | $-0.15 |
| Q3 2023 | $37.0M | -$4.1M | $-0.10 |
| Q2 2023 | $34.5M | -$6.7M | $-0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Axogen, Inc. Dividends, Buybacks & Capital Allocation
AXGN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Axogen, Inc. (CIK: 0000805928)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773864674.xml | View → |
| Mar 18, 2026 | 4 | xslF345X06/wk-form4_1773864598.xml | View → |
| Mar 2, 2026 | 4 | xslF345X05/wk-form4_1772493414.xml | View → |
| Mar 2, 2026 | 4 | xslF345X05/wk-form4_1772493371.xml | View → |
| Mar 2, 2026 | 4 | xslF345X05/wk-form4_1772493346.xml | View → |
❓ Frequently Asked Questions about AXGN
What is the AI rating for AXGN?
Axogen, Inc. (AXGN) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (HOLD) with 78% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are AXGN's key strengths?
Claude: Strong revenue growth of 20.2% YoY demonstrates market demand. Excellent gross margin of 74.3% indicates pricing power and operational efficiency in core business. ChatGPT: Revenue growth is strong at 20.2% YoY, showing continued commercial adoption. Gross margin of 74.3% suggests strong pricing power and favorable product economics.
What are the risks of investing in AXGN?
Claude: Persistent operating losses of -$7.8M indicate inability to convert revenue growth into profitability. Negative free cash flow of -$2.9M and operating cash flow of only $812K despite $225.2M revenue signals operational inefficiency. ChatGPT: Net income deteriorated 57.6% YoY, showing profitability remains fragile. Operating margin is still negative at -3.5%, so scale has not yet translated into sustained earnings.
What is AXGN's revenue and growth?
Axogen, Inc. reported revenue of $225.2M.
Does AXGN pay dividends?
Axogen, Inc. does not currently pay dividends.
Where can I find AXGN SEC filings?
Official SEC filings for Axogen, Inc. (CIK: 0000805928) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is AXGN's EPS?
Axogen, Inc. has a diluted EPS of $-0.34.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is AXGN a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Axogen, Inc. has a SELL rating with 78% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is AXGN stock overvalued or undervalued?
Valuation metrics for AXGN: ROE of -12.2% (sector avg: 15%), net margin of -7.0% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy AXGN stock in 2026?
Our dual AI analysis gives Axogen, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is AXGN's free cash flow?
Axogen, Inc.'s operating cash flow is $812.0K, with capital expenditures of $3.7M. FCF margin is -1.3%.
How does AXGN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -7.0% (avg: 12%), ROE -12.2% (avg: 15%), current ratio 5.11 (avg: 2).